8-K: Acro Biomedical Changes Auditors Amidst Going Concern Note

Acro Biomedical Co., Ltd. has appointed KCCW Accountancy Corp. as its new independent registered public accounting firm, replacing Prager Metis CPAs, LLC.

Summary

• Acro Biomedical Co., Ltd. dismissed Prager Metis CPAs, LLC as its independent registered public accounting firm on June 30, 2025.
• The company engaged KCCW Accountancy Corp. as its new independent registered accounting firm on June 30, 2025.
• There were no disagreements between the company and Prager Metis on any matter of accounting principles, financial statement disclosure, or auditing scope during the fiscal years ended December 31, 2024 and 2023, and the subsequent interim period.
• Prager Metis did not audit the company's financial statements for the years ended December 31, 2024 and 2023.
• Prager Metis's report on the company's financial statements for the year ended December 31, 2022, included an explanatory paragraph regarding the company's ability to continue as a going concern.
• The company did not consult with KCCW regarding accounting principles or audit opinions prior to their engagement.

Sentiment

Score: 3

Explanation: The dismissal of an auditor, especially one that previously issued a 'going concern' warning, is generally viewed negatively, even if no disagreements are cited. It raises questions about the company's financial health and stability.

Positives

• No disagreements were reported between Acro Biomedical and its former auditor, Prager Metis, regarding accounting principles, financial disclosures, or auditing procedures.
• The company promptly appointed a new independent registered accounting firm, KCCW Accountancy Corp., on the same day of the dismissal.

Negatives

• Prager Metis's audit report for the fiscal year ended December 31, 2022, included an explanatory paragraph concerning Acro Biomedical's ability to continue as a going concern.
• Prager Metis did not audit the company's financial statements for the fiscal years ended December 31, 2024 and 2023, indicating a gap or change in audit coverage prior to the dismissal.

Risks

• The explanatory paragraph in the December 31, 2022, audit report regarding the company's ability to continue as a going concern indicates significant financial uncertainty.
• A change in auditors, especially following a going concern qualification, can raise questions about financial stability and reporting transparency.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 1. 2025 ACRO BIOMEDICAL CO., LTD. By:/s/ Pao-Chi Chu Pao-Chi Chu Chief Executive Officer"

Industry Context

This event is specific to Acro Biomedical and does not directly reflect broader industry trends. Changes in auditors can occur for various reasons, but the prior "going concern" note makes this a company-specific concern rather than an industry-wide shift.

Corporate Governance

Stakeholder Impact

• Shareholders: May face increased uncertainty regarding the company's financial health due to the prior "going concern" warning and the change in auditors. The dismissal of an auditor, even without stated disagreements, can be a red flag.
• Investors: Will scrutinize future financial reports from the new auditor for clarity and assurance regarding the company's financial viability.
• Regulatory Authorities: The SEC will review the 8-K filing and the accompanying letter from the former auditor to ensure compliance and transparency in the change of accounting firms.

Next Steps

• Acro Biomedical will continue its operations with KCCW Accountancy Corp. as its new independent registered accounting firm.
• KCCW Accountancy Corp. will be responsible for auditing the company's future financial statements.

Key Dates

Recommendation

The filing indicates a change in auditors, which, while not inherently negative, is concerning given the previous auditor's 'going concern' explanatory paragraph for the 2022 financial statements. Although no disagreements were reported, the lack of audit for 2023 and 2024 by the outgoing firm, combined with the going concern issue, suggests significant financial instability and heightened risk. This situation warrants a 'sell' recommendation as it signals potential severe financial challenges and increased uncertainty for investors.

Keywords

Acro Biomedical, ACBM, auditor change, Prager Metis, KCCW Accountancy, independent accountant, going concern, SEC filing, 8-K, financial reporting, corporate governance